Compugen To Receive $5M Milestone Payment From AstraZeneca Following Dosing Of First Patient In Second Phase 3 Trial Of Rilvegostomig
Portfolio Pulse from Benzinga Newsdesk
Compugen will receive a $5 million milestone payment from AstraZeneca after dosing the first patient in the second Phase 3 trial of Rilvegostomig.
May 30, 2024 | 11:06 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Compugen will receive a $5 million milestone payment from AstraZeneca after dosing the first patient in the second Phase 3 trial of Rilvegostomig.
The milestone payment from AstraZeneca is a positive financial event for Compugen, indicating progress in their drug development and strengthening their financial position.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100